My research involves the use of animal models to study the behavioral pharmacology of addiction to nicotine and other drugs of abuse. The long-term goal of this work is to inform the development of more effective preventions and treatments for drug addiction. Specific areas of interest include: a) Development of models involving tobacco product exposure to inform FDA regulation of tobacco products and to understand the role of non-nicotine constituents in tobacco addiction; b) Role of negative affective (emotional) withdrawal symptoms and other factors in individual differences in vulnerability to drug addiction; c) Development of novel pharmacotherapies for addiction including the neuropeptide oxytocin and immunotherapy (vaccines and monoclonal antibodies). I use a number of behavioral models to address ion, place / taste conditioning, and locomotor sensitization.
(For a comprehensive list of recent publications, refer to PubMed, a service provided by the National Library of Medicine.)
- Berman ML, Bickel WK, Harris AC, LeSage MG, O'Connor RJ, Stepanov I, Shields PG, Hatsukami DK. Consortium on Methods Evaluating Tobacco: Research Tools to Inform FDA Regulation of Snus. Nicotine Tob Res. 2017 Oct 4. doi: 10.1093/ntr/ntx228.
- Harris AC, Muelken P, Smethells JR, Krueger M, LeSage MG. Similar precipitated withdrawal effects on intracranial self-stimulation during chronic infusion of an e-cigarette liquid or nicotine alone. Pharmacol Biochem Behav. 2017 Oct;161:1-5.
- LeSage MG, Staley M, Muelken P, Smethells JR, Stepanov I, Vogel RI, Pentel PR, Harris AC. Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats. Drug Alcohol Depend. 2016 Nov 1;168:76-88.
- Schmidt CE, Manbeck KE, Shelley D, Harris AC. Blockade of cholinergic transmission elicits somatic signs in nicotine-naïve adolescent rats. Front Pharmacol. 2015;6:239.
- Muelken P, Schmidt CE, Shelley D, Tally L, Harris AC. A two-day continuous nicotine infusion is sufficient to demonstrate nicotine withdrawal in rats as measured using intracranial self-stimulation. PLOS One. 2015;10(12):e0144553.
- Harris AC, Tally L, Schmidt CE, Muelken P, Stepanov I, Saha S, Isaksson Vogel R, LeSage MG. Animal models to assess the abuse liability of tobacco products: Effects of smokeless tobacco extracts on intracranial self- stimulation. Drug Alcohol Depend. 2015;147:60-67.
- Holtz NA, Radke AK, Zlebnik NE, Harris AC, Carroll ME. Intracranial self-stimulation reward thresholds during morphine withdrawal in rats bred for High (HiS) and low (LoS) saccharin intake. Brain Res. 2015;1602:119-126.
- Harris AC, Tally L, Muelken P, Banal A, Schmidt CE, Cao Q, LeSage MG. Effects of nicotine and minor tobacco alkaloids on intracranial self-stimulation in rats. Drug Alcohol Depend. 2015;153:330-334..
- Harris AC, LeSage MG, Shelley D, Perry JL, Pentel PR, Owens SM. The anti-(+)- methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)- methamphetamine effects on intracranial self-stimulation in rats. PLOS One. 2015;10(3): e0118787. doi:10.1371/journal.pone.0118787.
- Harris AC, Mattson C, Shelley D, LeSage MG. (2014). Restraint stress attenuates nicotine's locomotor stimulant but not discriminative stimulus effects in rats. Pharmacol Biochem Behav. 2014;124:92-100.
- Manbeck KE, Shelley D, Schmidt CE, Harris AC. Effects of oxytocin on nicotine withdrawal in rats. Pharmacol Biochem Behav. 2014;116:84-89.
- Raleigh MD, Pravetoni M, Harris AC, Birnbam AK, Pentel PR. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Therap. 2013;344:397-406.
- Hamilton KL, Harris, AC, Gewirtz, JC. Affective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration. Brain Res. 2013;1538:73-82.
- Harris AC,* Manbeck E, Schmidt CE, Shelley D. Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine. Psychopharmacology. 2013;225:291-302